The Group adheres to international standards in establishing a rigorous quality management system. Each subsidiary strictly follows pharmaceutical regulations and GMP requirements and operates an independent quality management department to fully execute quality assurance and control functions. Through continuous improvement and technological innovation, we optimize our quality management system to ensure its effectiveness and applicability. Our quality management system spans the entire product lifecycle, from procurement of raw and auxiliary materials and production to inspection and after-sales, ensuring stable and reliable product quality that meets both intended use specifications and registration requirements.

The Group has developed a scientific quality risk management system that encompasses GMP compliance and full lifecycle risk control for pharmaceutical products. Spanning R&D, technology transfer, commercial production, and product withdrawal, this system guides companies to accurately identify, analyze, evaluate, control quality risks and implements effective risk management, thereby reducing quality issues and ensuring drug safety and efficacy.

As one of China』s first comprehensively GMP-certified pharmaceutical companies, TUL continues to strengthen quality management and elevate product and service standards. Various bulk medicines have received certifications from the China Quality Certification Center (CQC), the China National Accreditation Service for Conformity Assessment (CNAS), the Certificate of Suitability to Monograph of European Pharmacopoeia(CEP), the U.S. Food and Drug Administration (FDA), the Hamburg Department of Health and Consumer Protection in Germany, and the Federal Committee for Protection from Sanitary Risks (COFEPRIS) in Mexico, demonstrating its global leadership in quality management.

Customer feedback serves as a key driver for our ongoing improvement. We highly value client evaluations and suggestions, vigorously address every complaint received, respond and improve through systematic follow-up procedures. In the event of adverse drug reactions, the Group handles these issues strictly in accordance with relevant regulations and protocols to ensure the health and safety of our users.

To ensure the safe, rational and effective use of medications for public health, the Group continuously strengthens its pharmacovigilance management system to guarantee comprehensive drug safety monitoring throughout the entire product lifecycle. We strictly adhere to the Pharmacovigilance Quality Management Practices, and have established independent pharmacovigilance departments responsible for the collection, handling and reporting of adverse drug reactions; drug risk identification, assessment and control; and post-marketing safety studies of drugs.